PT  - JOURNAL ARTICLE
AU  - Domagoj Kifer
AU  - Dario Bugada
AU  - Judit Villar-Garcia
AU  - Ivan Gudelj
AU  - Cristina Menni
AU  - Carole Sudre
AU  - Frano Vučković
AU  - Ivo Ugrina
AU  - Luca F Lorini
AU  - Margarita Posso
AU  - Silvia Bettinelli
AU  - Nicola Ughi
AU  - Alessandro Maloberti
AU  - Oscar Epis
AU  - Cristina Giannattasio
AU  - Claudio Rossetti
AU  - Livije Kalogjera
AU  - Jasminka Peršec
AU  - Luke Ollivere
AU  - Benjamin J Ollivere
AU  - Huadong Yan
AU  - Ting Cai
AU  - Guruprasad P. Aithal
AU  - Claire J Steves
AU  - Anu Kantele
AU  - Mikael Kajova
AU  - Olli Vapalahti
AU  - Antti Sajantila
AU  - Rafal Wojtowicz
AU  - Waldemar Wierzba
AU  - Zbigniew Krol
AU  - Artur Zaczynski
AU  - Katarina Zycinska
AU  - Marek Postula
AU  - Ivica Lukšić
AU  - Rok Čivljak
AU  - Alemka Markotić
AU  - Johannes Brachmann
AU  - Andreas Markl
AU  - Christian Mahnkopf
AU  - Benjamin Murray
AU  - Sebastien Ourselin
AU  - Ana M. Valdes
AU  - Juan P Horcajada
AU  - Xavier Castells
AU  - Julio Pascual
AU  - Massimo Allegri
AU  - Dragan Primorac
AU  - Tim D. Spector
AU  - Clara Barrios
AU  - Gordan Lauc
TI  - Effects of environmental factors on severity and mortality of COVID-19
AID  - 10.1101/2020.07.11.20147157
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.11.20147157
4099  - http://medrxiv.org/content/early/2020/12/14/2020.07.11.20147157.short
4100  - http://medrxiv.org/content/early/2020/12/14/2020.07.11.20147157.full
AB  - Background Most respiratory viruses show pronounced seasonality, but for SARS-CoV-2 this still needs to be documented.Methods We examined the disease progression of COVID-19 in 6,914 patients admitted to hospitals in Europe and China. In addition, we evaluated progress of disease symptoms in 37,187 individuals reporting symptoms into the COVID Symptom Study application.Findings Meta-analysis of the mortality risk in seven European hospitals estimated odds ratios per one day increase in the admission date to be 0.981 (0.973-0.988, p<0.001) and per increase in ambient temperature of one degree Celsius to be 0.854 (0.773-0.944, p=0.007). Statistically significant decreases of comparable magnitude in median hospital stay, probability of transfer to Intensive Care Unit and need for mechanical ventilation were also observed in most, but not all hospitals. The analysis of individually reported symptoms of 37,187 individuals in the UK also showed the decrease in symptom duration and disease severity with time.Interpretation Severity of COVID-19 in Europe decreased significantly between March and May and the seasonality of COVID-19 is the most likely explanation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the European Structural and Investment Funds grant for the National Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006), National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010) and IP CORONA-2020-04 grant from the Croatian Science Foundation. The Symptom Study app: Zoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. The Dept of Twin Research receives support from grants from the Wellcome Trust (212904/Z/18/Z) and the Medical Research Council (MRC)/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension (AIMHY; MR/M016560/1)., European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd, NIH and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. CM is funded by the Chronic Disease Research Foundation and by the MRC Aim-Hy project grant. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. In Zhejiang hospitals, ASST Papa Giovanni XXIII Hospital in Bergamo, Hospital del Mar in Barcelona and Helsinki University Hospital local ethics committees approved this retrospective study of COVID-19 patient data. For REGIOMED Hospital in Coburg, Ethics committee of the Bavarian state physician's association approved the study. In Nottingham University Hospital's trust, ASST GOM Niguarda, Warsaw and Zagreb this information was released as public statistical information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon a reasonable reequest.